AstraZeneca Reports Promising Data From Lung Cancer Trial
09 Agosto 2022 - 5:49AM
Noticias Dow Jones
By Ian Walker
AstraZeneca PLC said Tuesday that initial results from a trial
of datopotamab deruxtecan-based combinations show promising
clinical activity in patients with advanced non-small-cell lung
cancer.
The pharmaceutical giant said that the trial showed encouraging
efficacy and safety results that justify further studies.
Datopotamab deruxtecan is being jointly developed by AstraZeneca
and Daiichi Sankyo.
"We look forward to continuing this important research with the
goal of providing a new, effective treatment option for patients
with advanced non-small-cell lung cancer," Astra's Chief Medical
Officer and Oncology Chief Development Officer Cristian Massacesi
said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 09, 2022 06:34 ET (10:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024